Fluorescein Sodium

• SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre… Pending
  2023-509713-37-00 Phase II 1 country Hopital Fondation Adolphe De Rothschild
• A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003) Recruiting
  2025-524894-17-00 Phase II/III 10 countries Eyebiotech Limited
• “Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent n… Recruiting
  2023-505112-38-00 Phase III/IV 1 country Assistance Publique Hopitaux De Paris
• CELLVICROHN study: Is there a concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology to determine … Recruiting
  2024-517220-19-00 Phase III 1 country Centre Hospitalier Universitaire Amiens Picardie
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended
  2025-520809-12-00 Phase II/III 12 countries Eyebiotech Limited
• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema… Ended
  2024-510944-30-00 Phase II/III 12 countries Eyebiotech Limited
• A study to evaluate safety and efficacy of two different concentrations of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF… Ended
  2023-507561-26-00 Phase II 1 country Dompe' Farmaceutici S.p.A.
• A study to evaluate safety and efficacy of two different doses of Isocyclosporin A eye drop solution in patients with Atopic Keratoconjuncti… Ended
  2023-508907-19-00 Phase II 1 country Dompe' Farmaceutici S.p.A.
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 Phase III 14 countries Bayer AG
• Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (JAKUVEITE) Ended
  2024-513802-77-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 Phase III 10 countries Astellas Pharma Global Development Inc.
• A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended
  2023-509206-29-00 Phase III 4 countries Rophibio Inc.

Showing 1–12 of 12 trials